Consequences and therapeutic implications of macrophage apoptosis in atherosclerosis: the importance of lesion stage and phagocytic efficiency.
about
Diverse roles of macrophages in atherosclerosis: from inflammatory biology to biomarker discoveryMonocytes in atherosclerosis: subsets and functionsInduction of dendritic cell-like phenotype in macrophages during foam cell formationG2A deficiency in mice promotes macrophage activation and atherosclerosis.Macrophages in vascular inflammation--From atherosclerosis to vasculitisEmerging role of mast cells and macrophages in cardiovascular and metabolic diseasesApoptotic cell clearance: basic biology and therapeutic potential.Electronegative LDL: a circulating modified LDL with a role in inflammationPharmacological Treatment with Annexin A1 Reduces Atherosclerotic Plaque Burden in LDLR-/- Mice on Western Type DietTRAIL/DR5 signaling promotes macrophage foam cell formation by modulating scavenger receptor expressionPhagocyte-myocyte interactions and consequences during hypoxic wound healing.Liver X receptors at the intersection of lipid metabolism and atherogenesis"Eat me" imaging and therapyMouse models of atherosclerosis: a historical perspective and recent advances.Recent insights into the cellular biology of atherosclerosisABC Transport Proteins in Cardiovascular Disease-A Brief Summary.DBA/2J Haplotype on Distal Chromosome 2 Reduces Mertk Expression, Restricts Efferocytosis, and Increases Susceptibility to Atherosclerosis.Clearance of apoptotic cells: implications in health and diseaseInactivation of the adenosine A2A receptor protects apolipoprotein E-deficient mice from atherosclerosisSignal transducer and activator of transcription-1 is critical for apoptosis in macrophages subjected to endoplasmic reticulum stress in vitro and in advanced atherosclerotic lesions in vivo.Reduced apoptosis and plaque necrosis in advanced atherosclerotic lesions of Apoe-/- and Ldlr-/- mice lacking CHOP.Macrophage sphingomyelin synthase 2 deficiency decreases atherosclerosis in miceACAT inhibition reduces the progression of preexisting, advanced atherosclerotic mouse lesions without plaque or systemic toxicity.Cholesterol-induced membrane microvesicles as novel carriers of damage-associated molecular patterns: mechanisms of formation, action, and detoxification.Rab17 mediates differential antigen sorting following efferocytosis and phagocytosis.PI3K p110γ deletion attenuates murine atherosclerosis by reducing macrophage proliferation but not polarization or apoptosis in lesions.The impact of macrophage insulin resistance on advanced atherosclerotic plaque progression.Nutrient sensing and inflammation in metabolic diseases.The macrophage LBP gene is an LXR target that promotes macrophage survival and atherosclerosis.Macrophage LRP-1 controls plaque cellularity by regulating efferocytosis and Akt activation.Macrophage death and defective inflammation resolution in atherosclerosis.ABCG1 rs57137919G>a polymorphism is functionally associated with varying gene expression and apoptosis of macrophages.Inflammation and its resolution as determinants of acute coronary syndromes.Emerging applications of nanotechnology for the diagnosis and management of vulnerable atherosclerotic plaques.Class A scavenger receptor activation inhibits endoplasmic reticulum stress-induced autophagy in macrophageImpaired development of atherosclerosis in Abcg1-/- Apoe-/- mice: identification of specific oxysterols that both accumulate in Abcg1-/- Apoe-/- tissues and induce apoptosis.Efficient phagocytosis requires triacylglycerol hydrolysis by adipose triglyceride lipaseControl of macrophage activation and function by PPARs.Apolipoprotein E receptor-2 deficiency enhances macrophage susceptibility to lipid accumulation and cell death to augment atherosclerotic plaque progression and necrosis.Cholesterol and lipoprotein metabolism: Early Career Committee contribution
P2860
Q21285000-4FDF13B8-7DEA-417E-BCA2-8CC3CB825AE0Q22251045-987285E7-6DEC-4814-B107-19E7895E187DQ24294246-9FFD7A5C-C7F4-4F98-B5B5-24D3E44DB481Q24643942-24B5D3E9-EC90-47BA-9298-4BD3D5991C1FQ26825052-A622B0DA-EC9C-48A1-A438-517709169CB7Q26825467-03062132-8196-44E9-95F2-24165BD7F701Q26825935-8D971867-55BC-437E-BF76-390016424F98Q27015769-DC04641A-715B-4AD1-A666-3E1583157A08Q27303970-13E772D2-5733-419F-B271-2E3818C97BB6Q27325727-E4CA2167-9486-4622-846B-4196E407C642Q27690914-9D47E26F-A8AA-4369-891C-43844C42F488Q28082452-9E79EF13-8EB8-4109-AB42-B018C33F6467Q28394148-02401C13-A0E8-4C6F-9569-3647C5A406ADQ30238973-2AA136FD-3048-407B-8EEB-76FA1204F0BEQ30300194-4583BBA6-6A80-493F-94C0-CBBC3385D3ABQ30313271-520E3AF3-2A10-449B-B47E-5A137F9DEC1AQ30401679-8AF48234-A2E4-46B8-8B47-4525B5D4DCC2Q30433781-22832A65-02BE-46E7-BF86-FBBBF69F0108Q30435620-DD263BE5-39FB-425D-8CB5-2C8E8571D6C0Q30481584-394BB65A-0355-4B61-964B-8143AD3D4A6AQ30488194-1DC03054-B845-4B34-84A4-7314FAA5B863Q30490333-0B29F5AA-6CE4-4432-926E-AE1037E11E7FQ30538414-1E0A6E40-C2F9-4D7F-AD7A-84E10FC8D697Q30664287-0E7F684F-7FFA-419C-89F5-B8328E9F14A5Q30836198-EA3B81F8-C931-42DA-94BC-48E5D728950FQ31133175-82EB6F82-57DD-49F7-BEE7-810D0CED7793Q33586616-AC20372D-1412-41E0-9A4B-390A6DD4549AQ33623354-A4CA3B3F-562C-44E3-A384-3164A080AFA1Q33653635-F2A3DCD3-4AA0-4C37-8282-50316C55A43EQ33752988-658FB629-449A-439E-9AA4-383D950D5F29Q33789327-64F36358-5BCF-4581-8D2F-D26AE9BD0F39Q33817168-02113ED9-B3F9-41FF-A7CA-4EE3B82D6EB0Q33834800-3F244C9A-8CB0-4E51-99A8-BC23A8C68BB7Q33839384-2F6DE5B1-72A9-4E4B-9557-7AFE64762C32Q33858542-93C30FE6-87CE-49EE-92D0-02E58AA110E4Q33898636-1903D34F-66DD-4664-B054-AD3261B3AE80Q33924409-63B02ACF-0898-4E22-9D30-C15B04AFEC52Q33962601-8EFFE56F-FBF2-4153-BEE2-4E5BEE2F3DA2Q34016939-C9A42197-B5C8-4613-9C73-B04581F4A9A6Q34081210-52EB77CC-C2E1-42A4-84C2-28FB5ADDB56C
P2860
Consequences and therapeutic implications of macrophage apoptosis in atherosclerosis: the importance of lesion stage and phagocytic efficiency.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Consequences and therapeutic i ...... age and phagocytic efficiency.
@ast
Consequences and therapeutic i ...... age and phagocytic efficiency.
@en
type
label
Consequences and therapeutic i ...... age and phagocytic efficiency.
@ast
Consequences and therapeutic i ...... age and phagocytic efficiency.
@en
prefLabel
Consequences and therapeutic i ...... age and phagocytic efficiency.
@ast
Consequences and therapeutic i ...... age and phagocytic efficiency.
@en
P1476
Consequences and therapeutic i ...... age and phagocytic efficiency.
@en
P2093
P304
P356
10.1161/01.ATV.0000184783.04864.9F
P407
P577
2005-09-01T00:00:00Z